呲仑帕奈所致的严重不良反应有什么？出现后怎么处理？

Japanese pharmaceutical company Eisai recently announced that it has launched a new generation of anti-epileptic drug Fycompa (generic name: perampanel) in China. The drug is a once-daily tablet for the auxiliary treatment of partial-onset epilepsy (with or without secondary generalized epilepsy) in patients with epilepsy aged 12 years and above. Fycompa's New Drug Application (NDA) was submitted in September 2018, and China's National Medical Products Administration (NMPA) granted Fycompa priority review status in January 2019 due to significant clinical benefits over existing drugs, and approved Fycompa in September 2019.

What are the serious adverse reactions caused by Parampanel? What to do after it appears? : The most common adverse reactions of valampanel reported in adverse reaction regulatory trials are dizziness, drowsiness, fatigue, irritability, nausea, falls and weight gain. At the same time, the biggest problem with the use of perampanel is that at daily doses of 8 mg or more, perampanel can easily cause or worsen mental and behavioral adverse events, especially anger, hostility, and aggression. Regarding changes in cognitive function, a study in the United States and the United Kingdom conducted a follow-up assessment of cognitive function in 12 to 18-year-old patients with focal epilepsy treated with parampanel. The results showed that there was no difference in overall cognitive scores between the parampanel treatment group and the placebo group, but there were subtle differences in some other areas: Compared with the placebo group, patients treated with parampanel showed some improvement in episodic memory ability, but their continuous attention and memory speed declined. Overall, parampanel has less impact on cognitive function in children. If serious adverse reactions occur during medication, you need to go to the hospital for examination in time and consult the relevant doctor to determine the follow-up treatment plan.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.